Enovis (NYSE:ENOV) Research Coverage Started at BTIG Research

BTIG Research assumed coverage on shares of Enovis (NYSE:ENOV) in a research report report published on Tuesday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $41.00 price objective on the stock.

A number of other research firms have also recently weighed in on ENOV. Canaccord Genuity Group lowered their price objective on Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, December 17th. Wells Fargo & Company upped their price objective on shares of Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enovis in a research note on Wednesday, October 8th. UBS Group restated a “buy” rating and set a $50.00 price target on shares of Enovis in a research note on Monday. Finally, Evercore ISI set a $40.00 price objective on shares of Enovis in a research note on Monday. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $46.71.

Enovis Price Performance

Shares of ENOV stock opened at $28.82 on Tuesday. The stock’s 50-day moving average is $28.39 and its 200 day moving average is $29.91. Enovis has a 1-year low of $25.47 and a 1-year high of $49.38. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.22 and a quick ratio of 1.16. The company has a market cap of $1.65 billion, a P/E ratio of -1.22 and a beta of 1.52.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Monday, January 8th. The company reported $0.59 EPS for the quarter. Enovis had a negative net margin of 61.22% and a positive return on equity of 7.79%. The business had revenue of $383.81 million during the quarter. Enovis has set its FY 2025 guidance at 3.100-3.250 EPS. Research analysts predict that Enovis will post 2.79 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Enovis news, insider John Kleckner bought 2,468 shares of the stock in a transaction on Tuesday, November 25th. The shares were bought at an average price of $30.32 per share, with a total value of $74,829.76. Following the purchase, the insider directly owned 12,302 shares in the company, valued at $372,996.64. This trade represents a 25.10% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Daniel A. Pryor sold 999 shares of the company’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $27.20, for a total value of $27,172.80. The SEC filing for this sale provides additional information. Insiders own 2.70% of the company’s stock.

Institutional Trading of Enovis

Several hedge funds have recently added to or reduced their stakes in ENOV. Farther Finance Advisors LLC boosted its holdings in Enovis by 42.8% in the third quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock valued at $37,000 after purchasing an additional 367 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after acquiring an additional 707 shares in the last quarter. Elevation Point Wealth Partners LLC acquired a new position in Enovis in the second quarter valued at $46,000. SJS Investment Consulting Inc. grew its holdings in shares of Enovis by 30,340.0% during the third quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock worth $46,000 after purchasing an additional 1,517 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in shares of Enovis by 353.5% during the fourth quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock worth $49,000 after purchasing an additional 1,446 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.